Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial
Researchers continue to investigate NAD+ in relation to: NAD+ serves as an essential cofactor in metabolic pathways involved in cellular energy production and redox reactions
Safety parameters evaluated included blood tests (measurement of AST, ALT, -glutamyl transpeptidase, hemoglobin, bilirubin levels and PT) and no patients had severe side effects, with one patient having mild diarrhea
The company positions itself as a cost-conscious option for accessing prescription weight-loss medications through a fully virtual model
Reference lists from key publications were also reviewed to identify additional relevant studies
Obesity was a comorbidity in six cases